Vera Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Vera Therapeutics, Inc. (VERA) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$247.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-10
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$247.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$942.00K, a 460.92% decline year-over-year.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was -$95.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $354.00K, a 76.31% decline year-over-year.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2025 was $393.00K, a 176.76% increase from fiscal 2024.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was $142.00K, a 43.43% decline from fiscal 2023.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $251.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$224.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$247.00K 10-Q · filed 2026-08-10 | -$1.19M 10-Q · filed 2026-08-10 | -$1.28M derived: sum of 3 quarters · filed 2026-08-10 | -$930.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$942.00K 10-Q · filed 2026-05-07 | -$1.04M derived: sum of 2 quarters · filed 2026-05-07 | -$683.00K derived: sum of 3 quarters · filed 2026-05-07 | -$810.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $259.00K derived: sum of 2 quarters · filed 2026-02-26 | $132.00K derived: sum of 3 quarters · filed 2026-08-10 | $393.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $354.00K 10-Q · filed 2025-11-05 | $227.00K derived: sum of 2 quarters · filed 2026-08-10 | $488.00K 10-Q · filed 2025-11-05 | -$163.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$127.00K 10-Q · filed 2026-08-10 | $134.00K 10-Q · filed 2026-08-10 | -$517.00K derived: sum of 3 quarters · filed 2026-08-10 | $977.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $261.00K 10-Q · filed 2026-05-07 | -$390.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.10M derived: sum of 3 quarters · filed 2026-05-07 | $827.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$651.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $843.00K derived: sum of 2 quarters · filed 2026-02-26 | $566.00K derived: sum of 3 quarters · filed 2026-02-26 | $142.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.49M 10-Q · filed 2025-11-05 | $1.22M derived: sum of 2 quarters · filed 2025-11-05 | $793.00K 10-Q · filed 2025-11-05 | $895.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$277.00K 10-Q · filed 2025-08-05 | -$700.00K 10-Q · filed 2025-08-05 | -$599.00K derived: sum of 3 quarters · filed 2026-02-26 | -$532.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$424.00K 10-Q · filed 2025-05-07 | -$322.00K derived: sum of 2 quarters · filed 2026-02-26 | -$255.00K derived: sum of 3 quarters · filed 2026-02-26 | -$393.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $169.00K derived: sum of 2 quarters · filed 2026-02-26 | $31.00K derived: sum of 3 quarters · filed 2026-02-26 | $251.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $67.00K 10-Q · filed 2024-11-07 | -$71.00K derived: sum of 2 quarters · filed 2024-11-07 | $149.00K 10-Q · filed 2024-11-07 | $204.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$138.00K 10-Q · filed 2024-08-08 | $82.00K 10-Q · filed 2024-08-08 | $137.00K derived: sum of 3 quarters · filed 2024-08-08 | $10.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $220.00K 10-Q · filed 2024-05-10 | $275.00K derived: sum of 2 quarters · filed 2024-05-10 | $148.00K derived: sum of 3 quarters · filed 2024-05-10 | $8.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$72.00K derived: sum of 2 quarters · filed 2024-03-27 | -$212.00K derived: sum of 3 quarters · filed 2024-03-27 | -$224.00K 10-K · filed 2024-03-27 |
| 2022-09-30 | -$127.00K 10-Q · filed 2023-11-09 | -$267.00K derived: sum of 2 quarters · filed 2023-11-09 | -$279.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$140.00K 10-Q · filed 2023-08-10 | -$152.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$12.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |